It differs from the ADCS-CGIC used in AD trials mainly in its shorter length and its The CGIC rating is made on a 7-point Likert-type scale where change from. Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ in Alzheimer Disease Assessment Scale-cognitive, Activities of Daily Living. A mandate of the ADCS is to develop optimal assessment instruments for use in Living (ADL), and the Clinical Global Impression of Change Scale (CGIC).
|Genre:||Health and Food|
|Published (Last):||25 March 2017|
|PDF File Size:||17.86 Mb|
|ePub File Size:||6.2 Mb|
|Price:||Free* [*Free Regsitration Required]|
We used a generalized estimating equations approach for ordinal outcome data to test the effects of treatment, baseline characteristics, and change in clinical measures on the MCI-CGIC over 12 months, and ordinal logistic regression to assess the association between MCI-CGIC and change in clinical measures at 6 months and 12 months.
The difference in magnitude of the MCI-CGIC between donepezil or vitamin E treatment compared to placebo was similar to other secondary clinical outcomes – both significant and not – in a trial in which the medications did not show overall advantages compared to placebo.
Hypothesis 1, drug v. Insel report that they have no relationships to disclose. Because there might be differences in CGIC change based on baseline cognitive severity, the sample was split at the median ADAScog point into a higher scoring and lower scoring group. Methods We used a generalized estimating equations approach for ordinal outcome data to test the effects of treatment, baseline characteristics and change in clinical measures on the MCI-CGIC over 12 months, and ordinal logistic regression to assess the association between MCI-CGIC and change in clinical measures at 6 months and 12 months.
ADRC – CGIC page
The publisher’s final edited version of this article is available at Alzheimer Dis Assoc Disord. AU – Morris, John C. Additionally, for hypothesis 3, not only does the CGIC change over time, but the values of the predictors clinical variables also change over time.
We compared subject-ratings with partner-ratings, clinic-based with home-based ratings, and ratings based on severity as determined by the Clinical Dementia Rating scale. Weights were calculated as the reciprocal of the sum of the correlation coefficients between the tests in each domain at baseline.
For clinic use, please describe: At baseline only, clinical information about the subject may be used, including medical history, physical and neurological examination, and other ratings done at screening.
Schmitt reports past clinical trial grant support from Pfizer.
Variables at screening or baseline that were associated with worse CGIC scores over 6 and 12 months included white race, greater years of education, worse depression, dementia severity rating, cognitive, and daily activities scores, and lower memory domain scores on a neuropsychological battery. An inventory to assess activities of daily living for clinical trials in Alzheimer’s disease.
Alzheimer Disease and Associated Disorders23 3 Do not redistribute the downloaded material; instead, tell interested parties to contact svale and complete their own request form and we will send the download link directly to them.
The goals of this investigation were to assess the feasibility of the use of this modified ADCS-CGIC in MCI clinical trials by assessing whether or not the CGIC scald a medication effect, whether or not baseline demographic or clinical characteristics predicted change, and whether or not there was an association between MCI-CGIC change and change in other clinical measures, to assess external or concurrent validity.
In particular, increases in CDR-sb scores that reflect clinical progression of disease severity without reference to baseline functioning were associated with increasing CGIC ratings, providing additional evidence for the validity of this CGIC rating approach in MCI.
CGIC or ADCS-CGIC:
ClarkMD, 5 John C. Doody, Philip Insel, Christopher M. There are two major reasons for this: CGIC scales have been used extensively as primary outcomes in phase 2 and 3 clinical trials for Alzheimer disease, mild cognitive impairment, and for cognitive enhancers. Results were similar whether scwle 3-category or 2-category model was used Table 2Figure 1.
Access to Document Qizilbash N, et al. There was no statistically significant effect between treatment groups.
Although a common approach of analyzing CGIC in clinical trials has been to treat the variable as a continuous outcome, we chose to use the CGIC as an ordinal outcome and take advantage of the ordinal models that are available for such data such as the GEE rather than simply analyzing an ordinal outcome as a continuous outcome.
No adjustments for multiple comparisons were made given the exploratory nature of the hypotheses. Downloads that will be available after satisfactory completion of the Request Form.
The GEE approach models the longitudinal experience of the study patients and provides information on change over a period of time, while the fixed-effects model which models cross-sectional data does not. Regression models with ordinal variables. The MCI-CGIC also predicted changes in clinical ratings scales at 6 and 12 months, thus providing evidence for its external or concurrent validity.
The Alzheimer’s Disease Cooperative Study. Author information Copyright and License information Disclaimer. Variables at screening or baseline that were associated with worse CGIC scores over 6 and 12 months included white race, greater years of education, worse depression, dementia severity rating, cognitive, and daily activities scores, and lower memory domain scores on a neuropsychological battery.
GEE adc-cgic for binary data assuming a logistic function and ordinal data using a proportional odds model were used for the two models. Criteria used by drug regulatory authorities. Neurology Health Sciences Adcs-cgc.